

Are NK-CAR-cells the future of NK-cell therapy? No

Abstract:

NK cells can achieve complete remission and serve as a bridge to allogeneic transplant in patients with refractory AML. Limitations of current NK cell strategies include single donor products, allogeneic persistence and tumor specificity. To enhance specificity, **Tri**-specific **K**iller **E**ngagers (TriKEs containing an NK cell anti-CD16, an IL-15 linker, and a tumor associated antigen engager) can be used alone or with adoptive transfer. Multi-dosing will be achieved with off-the-shelf genetically modified induced pluripotent stem cells overexpressing CD16 as a renewable NK cell source. These alone or in combination with TriKE may be more effective than current NK-CAR strategies.